Acupuncture (PDQ®)–Health Professional Version

Changes to This Summary (02/06/2019)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Human/Clinical Studies

Revised Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, and Table 8 to include level of evidence 1sC.

The Acupuncture for aromatase inhibitor-associated musculoskeletal symptoms subsection was extensively revised.

Added Chemotherapy-induced peripheral neuropathy (CIPN) from platinum-containing agents or taxanes as a new subsection.

Added CIPN from bortezomib or thalidomide as a new subsection.

This summary is written and maintained by the PDQ Integrative, Alternative, and Complementary Therapies Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Summary of the Evidence for Acupuncture Treatment of Cancer-Related Symptoms

Next section >
About This PDQ Summary